Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure- Contra.
8 November 2019 (14:30 - 14:40)
Organised by:
Slides
About the speaker
University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
5 More presentations in this session
Associate Professor D. Sim (Singapore, SG)
PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Pro.
Professor M. Marwan (Erlangen, DE)
Associate Professor K. Sin (Singapore, SG)
Access the full session
The Event
ESC Asia with APSC & AFC
8 November 2019
14:30 CET
You may be interested in
Congress Session
